What is the recommended way to transition from Lyrica (pregabalin) to gabapentin?

Transitioning from Lyrica to Gabapentin

When transitioning from pregabalin (Lyrica) to gabapentin in the inpatient setting, use a direct switch strategy rather than a cross-taper, as this approach is successful in 95% of cases and is particularly effective in patients with normal renal function 1.

Recommended Transition Strategy

Direct Switch Approach (Preferred)

The most practical method is to stop pregabalin and immediately start gabapentin at an appropriate equivalent dose. This strategy is supported by real-world evidence showing high success rates with stable or improved pain control 1.

Starting gabapentin dosing:

• Begin at 100-300 mg at bedtime or 100-300 mg three times daily
• Increase by 100-300 mg every 1-7 days as tolerated
• Target maintenance dose: 300-600 mg three times daily (900-1800 mg/day)
• Maximum dose: 3600 mg/day in three divided doses 2

Key Pharmacokinetic Differences to Consider

Pregabalin has linear pharmacokinetics while gabapentin has nonlinear, saturable absorption 2. This means:

• Pregabalin provides more predictable dosing and faster titration (can reach therapeutic dose in 1 week)
• Gabapentin requires slower, more careful titration due to absorption limitations
• Maximum time between gabapentin doses should not exceed 12 hours 3
• An adequate trial of gabapentin can require 2 months or more (3-8 weeks for titration plus 2 weeks at maximum dose) 2

Dosing Considerations

Do not attempt direct dose conversion between pregabalin and gabapentin. Instead:

1. Assess the patient's current pain control on pregabalin
2. Start gabapentin at standard initial doses (100-300 mg TID) regardless of pregabalin dose
3. Titrate upward based on response, not based on the previous pregabalin dose
4. Expect a longer titration period compared to pregabalin (weeks vs. days)

Critical Pitfalls to Avoid

Renal function adjustment is mandatory for both medications:

• Both require dose reduction in renal insufficiency 2
• Use creatinine clearance to guide dosing adjustments 3
• For gabapentin in patients with CrCl <60 mL/min, reduce frequency and total daily dose proportionally 3

Common adverse effects to monitor:

• Both cause dose-dependent dizziness and sedation 2
• These can be minimized by starting low and titrating slowly
• Warn patients about potential temporary worsening of side effects during transition

Misuse potential:

• Both gabapentinoids carry misuse risk, particularly in patients with substance use disorders or when combined with opioids 4, 5
• Concomitant use with opioids or benzodiazepines significantly increases overdose risk 4
• Monitor for signs of misuse, especially in high-risk populations

Alternative: Cross-Taper Strategy

If the direct switch fails or in patients with severe, unstable pain:

• Gradually reduce pregabalin while simultaneously increasing gabapentin
• This approach showed 78% success rate in one study 1
• Consider this in patients with poor renal function (eGFR <50 mL/min/1.73 m²) where direct switch may be less successful 1

Timeline Expectations

Set realistic expectations with patients:

• Pain relief may not be immediate with gabapentin
• Full therapeutic effect requires 4-8 weeks of titration
• Some patients may experience temporary pain increase during transition
• Gabapentin provides similar efficacy to pregabalin once therapeutic doses are reached 2

When to Avoid Gabapentin

Exercise caution or consider alternatives in:

• Patients requiring rapid pain control (pregabalin works faster)
• Severe renal impairment (complex dosing adjustments required)
• History of substance abuse (both carry misuse risk, but pregabalin is Schedule V) 2
• Patients with nerve compression syndromes where caution is warranted 6